MY207509A - Treatment of asthma with anti-tslp antibody - Google Patents

Treatment of asthma with anti-tslp antibody

Info

Publication number
MY207509A
MY207509A MYPI2019005927A MYPI2019005927A MY207509A MY 207509 A MY207509 A MY 207509A MY PI2019005927 A MYPI2019005927 A MY PI2019005927A MY PI2019005927 A MYPI2019005927 A MY PI2019005927A MY 207509 A MY207509 A MY 207509A
Authority
MY
Malaysia
Prior art keywords
asthma
treatment
tslp antibody
tslp
antibody
Prior art date
Application number
MYPI2019005927A
Other languages
English (en)
Inventor
R Parnes Jane
Griffiths Janet
Original Assignee
Amgen Inc
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Medimmune Llc filed Critical Amgen Inc
Publication of MY207509A publication Critical patent/MY207509A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MYPI2019005927A 2017-04-12 2018-04-12 Treatment of asthma with anti-tslp antibody MY207509A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762484864P 2017-04-12 2017-04-12
US201762553477P 2017-09-01 2017-09-01
US201762553575P 2017-09-01 2017-09-01
PCT/US2018/027271 WO2018191479A1 (en) 2017-04-12 2018-04-12 Treatment of asthma with anti-tslp antibody

Publications (1)

Publication Number Publication Date
MY207509A true MY207509A (en) 2025-02-28

Family

ID=62092313

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019005927A MY207509A (en) 2017-04-12 2018-04-12 Treatment of asthma with anti-tslp antibody

Country Status (22)

Country Link
US (3) US10828365B2 (enExample)
EP (1) EP3609917A1 (enExample)
JP (4) JP7330896B2 (enExample)
KR (2) KR102666879B1 (enExample)
CN (1) CN110573525A (enExample)
AU (2) AU2018253118B2 (enExample)
BR (1) BR112019021482A2 (enExample)
CA (1) CA3059364A1 (enExample)
CL (1) CL2019002897A1 (enExample)
CO (1) CO2019011462A2 (enExample)
IL (1) IL269791B (enExample)
JO (1) JOP20190243B1 (enExample)
MX (1) MX2019012158A (enExample)
MY (1) MY207509A (enExample)
PE (1) PE20200484A1 (enExample)
PH (1) PH12019502331A1 (enExample)
SG (1) SG11201909322VA (enExample)
TN (1) TN2019000289A1 (enExample)
TW (2) TWI856945B (enExample)
UA (1) UA130334C2 (enExample)
UY (1) UY37676A (enExample)
WO (1) WO2018191479A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3842457A1 (en) * 2015-09-09 2021-06-30 Novartis AG Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
EP3609917A1 (en) * 2017-04-12 2020-02-19 Amgen Inc. Treatment of asthma with anti-tslp antibody
TWI917325B (zh) * 2019-06-04 2026-03-11 大陸商江蘇恆瑞醫藥股份有限公司 能結合胸腺基質淋巴細胞生成素的抗體及其應用
US12435131B2 (en) 2019-07-11 2025-10-07 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with thymic stromal lymphopoietin (TSLP)-receptor signaling
JP7331298B2 (ja) * 2019-09-04 2023-08-23 ビオシオン インコーポレイテッド 抗体結合tslp及びその使用
UA129038C2 (uk) * 2019-10-28 2024-12-25 Медіммуне Лімітед Сухий порошкоподібний склад антитіла, що зв'язує тимічний стромальний лімфопоетин (tslp)
CN114887053B (zh) * 2019-11-29 2026-04-24 康诺亚生物医药科技(成都)有限公司 一种tslp相关病症治疗剂的开发和应用
EP4047019A4 (en) * 2019-12-13 2023-11-15 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-tslp antibody and uses thereof
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法
CR20220457A (es) * 2020-02-13 2023-01-09 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria
EP4103605A1 (en) * 2020-02-13 2022-12-21 Amgen Inc. Treatment of atopic dermatitis with anti-tslp antibody
MX2022010120A (es) * 2020-02-18 2022-09-05 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y metodos de uso de los mismos.
CN113388035B (zh) * 2020-03-13 2026-02-27 迈威(上海)生物科技股份有限公司 特异性针对人tslp的抗体及其应用
WO2022117079A1 (zh) * 2020-12-03 2022-06-09 江苏恒瑞医药股份有限公司 结合胸腺基质淋巴细胞生成素的抗体及其应用
CN113501878B (zh) * 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
CN114853888B (zh) * 2021-02-05 2023-11-03 上海洛启生物医药技术有限公司 抗tslp纳米抗体及其应用
TWI915520B (zh) * 2021-03-03 2026-02-21 大陸商正大天晴藥業集團股份有限公司 含抗tslp抗體的藥物組合物
CR20230533A (es) * 2021-04-19 2024-04-05 Medimmune Ltd Un fab anti-tslp con estabilidad mejorada
KR20230175245A (ko) 2021-04-23 2023-12-29 암젠 인크 변형된 항-tslp 항체
US20240190951A1 (en) 2021-04-23 2024-06-13 Amgen Inc. Anti-tslp antibody compositions and uses thereof
CA3217029A1 (en) * 2021-05-30 2022-12-08 Biolojic Design Ltd. Engineered dual binding antibodies and uses thereof
CN113683694B (zh) 2021-09-03 2022-05-13 江苏荃信生物医药股份有限公司 一种抗人tslp单克隆抗体及其应用
CN117209604B (zh) * 2021-12-02 2024-03-22 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN117327176B (zh) * 2022-06-24 2026-08-04 南京融捷康生物科技有限公司 一种抗tslp的单域抗体及其用途
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
TW202426485A (zh) 2022-10-26 2024-07-01 美商安進公司 抗tslp抗體組成物及其用途
IL326774A (en) * 2023-08-25 2026-04-01 Proteologix Us Inc Anti-tslp antibody constructs and uses thereof
AR133647A1 (es) 2023-08-25 2025-10-22 Proteologix Us Inc Constructos de anticuerpos multiespecíficos anti-il-13 y usos de los mismos
CN117551195B (zh) * 2024-01-12 2024-04-09 杭州畅溪制药有限公司 靶向tslp的vhh纳米抗体及其应用
WO2025179220A1 (en) * 2024-02-22 2025-08-28 Flagship Pioneering Innovations Vi, Llc Dosing of antigen binding molecules targeting thymic stromal lymphopoietin (tslp)
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease
WO2026076381A1 (en) * 2024-10-04 2026-04-09 Prana Therapies, Inc. Il-4r and tslp inhibitors and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
TW201018482A (en) 2008-08-08 2010-05-16 Glaxo Wellcome Mfg Pte Ltd Novel treatment
EP3594356A1 (en) 2009-11-04 2020-01-15 Merck Sharp & Dohme Corp. Engineered anti-tslp antibody
AR082163A1 (es) 2010-07-15 2012-11-14 Hoffmann La Roche Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
JP6715767B2 (ja) * 2013-10-23 2020-07-01 ジェネンテック, インコーポレイテッド 好酸球性疾患の診断及び治療方法
EA201790342A1 (ru) * 2014-08-08 2017-07-31 ЭЛЕКТОР ЭлЭлСи Антитела к trem2 и способы их применения
CN107428828A (zh) * 2015-03-11 2017-12-01 葛兰素史密斯克莱知识产权发展有限公司 Tslp结合蛋白
EA038332B1 (ru) 2015-09-09 2021-08-10 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
EP3609917A1 (en) * 2017-04-12 2020-02-19 Amgen Inc. Treatment of asthma with anti-tslp antibody

Also Published As

Publication number Publication date
IL269791B (en) 2022-07-01
TWI856945B (zh) 2024-10-01
TN2019000289A1 (en) 2021-05-07
JP2023099233A (ja) 2023-07-11
TW201838652A (zh) 2018-11-01
KR20190140956A (ko) 2019-12-20
TW202523688A (zh) 2025-06-16
UA130334C2 (uk) 2026-01-28
JOP20190243B1 (ar) 2024-12-22
AU2018253118A1 (en) 2019-10-24
US10828365B2 (en) 2020-11-10
KR102666879B1 (ko) 2024-05-23
KR20240070727A (ko) 2024-05-21
BR112019021482A2 (pt) 2020-05-12
JP2020516647A (ja) 2020-06-11
JP2025170430A (ja) 2025-11-18
US20250032608A1 (en) 2025-01-30
PH12019502331A1 (en) 2020-09-28
CN110573525A (zh) 2019-12-13
JP2024150751A (ja) 2024-10-23
CL2019002897A1 (es) 2020-03-06
PE20200484A1 (es) 2020-03-03
JP7330896B2 (ja) 2023-08-22
JOP20190243A1 (ar) 2019-10-13
CA3059364A1 (en) 2018-10-18
MX2019012158A (es) 2019-12-16
CO2019011462A2 (es) 2019-10-31
US20180296669A1 (en) 2018-10-18
JP7894910B2 (ja) 2026-07-24
US20210052726A1 (en) 2021-02-25
IL269791A (en) 2019-11-28
UY37676A (es) 2018-10-31
EP3609917A1 (en) 2020-02-19
WO2018191479A1 (en) 2018-10-18
AU2025204735A1 (en) 2025-07-17
AU2018253118B2 (en) 2025-04-10
SG11201909322VA (en) 2019-11-28

Similar Documents

Publication Publication Date Title
PH12019502331A1 (en) Treatment of asthma with anti-tslp antibody
MY203971A (en) Anti-lag-3 antibodies and compositions
PH12018502113A1 (en) Chimeric receptors and methods of use thereof
MX2022012749A (es) Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas.
MY210545A (en) Chimeric receptors to flt3 and methods of use thereof
MY205760A (en) Humanized antibodies against c-kit
BR112017008710A8 (pt) Composições e métodos para estimular a eficácia de imunoterapia celular adotiva
NZ743124A (en) Antibodies targeting fc receptor-like 5 and methods of use
AU2016320748A8 (en) Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
WO2013006474A3 (en) Requlatora t cells and methods of identifying and isolating them using cd6 -expression or the combination of cd4, cd25 and cd127
SG10201808835QA (en) Anti-siglec-8 antibodies and methods of use thereof
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
PH12018502137A1 (en) Anti-complement factor bb antibodies and uses thereof
MX2020010722A (es) Anticuerpos anti-cd40 para uso en la prevencion del rechazo de injertos.
ZA202205936B (en) Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof
PH12020550023A1 (en) Compositions for treating stress-related disorders
MX2025008918A (es) Tratamiento para la rinosinusitis cronica con anticuerpos anti-tslp
MY192390A (en) Method for isolation of stem cells from bone marrow using subfractionation culturing method and proliferation thereof
MY201744A (en) Binding polypeptides and methods of making the same
MX2019013160A (es) Metodos de tratamiento selectivo del asma usando antagonistas de il-17.
JOP20250290A1 (ar) علاج الربو المعتمد على كورتيكوستيرويد بجسم مضاد لـ tslp
MX2017014217A (es) Procedimiento in vitro de proliferacion de celulas madre y uso de un dispositivo para incrementar la proliferacion de celulas madre in vitro.
MX2010007355A (es) Extracto de heteropterys brachiata, metodo de obtencion y uso para el tratamiento de ansiedad y depresion.